Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> MutationRichard M. Stone, Hartmut Döhner, Sumithra J. Mandrekar et al.|New England Journal of Medicine|2017Cited by 2.2k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Stéphane de Botton et al.|Blood|2017Cited by 1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Hagop M. Kantarjian, Eytan M. Stein et al.|New England Journal of Medicine|2018Cited by 1.4k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic LeukemiaSteven L. Soignet, Raymond P. Warrell, Stanley R. Frankel et al.|Journal of Clinical Oncology|2001Cited by 825
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaTait D. Shanafelt, Martin S. Tallman, Xin V. Wang et al.|New England Journal of Medicine|2019Cited by 735